| Literature DB >> 33806781 |
Alexandr G Kruchinin1, Olga S Savinova2, Olga A Glazunova2, Konstantin V Moiseenko2, Evgeniya Yu Agarkova1, Tatyana V Fedorova2.
Abstract
Whey protein hydrolysates (WPHs) are one of the most promising sources of biofunctional peptides with such beneficial properties as antioxidant, antihypertensive, anti-inflammatory and others. WPHs also could be used as foaming agents for aerated products (e.g., milk shake type drinks). However, WPH alone has a bitter taste and foamed WPH should be stabilized by additional ingredients. Here, we present a composition including WPH and three polysaccharides-pumpkin pectin, sodium alginate and ι-carrageenan-used as foam stabilizers. Polysaccharide content was selected according to foaming, organoleptic antioxidant and angiotensin-I-converting enzyme inhibitory characteristics of the resulted composition. Further, the hypotensive, antioxidant and hepatoprotective properties of the composition were proved by in vivo tests performed in spontaneously hypertensive rats and Wistar rats with CCl4-induced hepatic injury.Entities:
Keywords: TBARS; angiotensin I-converting enzyme inhibition (ACE-I); antihypertensive effect; carbon tetrachloride-induced oxidative stress; foaming; functional food; hepatoprotection; polysaccharides; spontaneously hypertensive rats (SHRs); whey-protein hydrolysate
Year: 2021 PMID: 33806781 PMCID: PMC8004872 DOI: 10.3390/nu13031031
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Experimental design.
The rheological, foam-forming and functional properties of compositions comtaining whey protein hydrolysates and plant polysaccharides (WPH–PS).
| Properties | Polysaccharide Ratio | ||||
|---|---|---|---|---|---|
| A:C:P * 1:3:2 | A:C:P 2:3:1 | A:C:P 3:2:1 | A:C:P 1:1:1 | A:C:P 2:1:3 | |
| Sample 1 | Sample 2 | Sample 3 | Sample 4 | Sample 5 | |
| Viscosity, mPa·s | 158 | 183 | 338 | 146 | 74 |
| Foam capacity, % | 280 | 400 | 340 | 360 | 380 |
| Foam stability, min | 41 | 48 | 35 | 27 | 15 |
| Zeta potential, mV | −20.1 | −23.7 | −24.5 | −20.1 | −17.5 |
| ORAC, µmol(TE)·g−1(protein) | 418.3 | 393.4 | 399.3 | 405.4 | 407.9 |
| ACE-I activity (IC50), mg(protein)·mL−1 | 1.66 | 1.07 | 1.27 | 1.01 | 0.813 |
* A—sodium alginate, C—ι-carrageenan, P—pumpkin pectin.
Figure 2The bubble size and bubble homogeneity of WPH–PS compositions.
Figure 3The organoleptic properties of WPH–PS compositions.
Figure 4The in vivo assessment of antihypertensive properties for WPH–PS composition using Spontaneously Hypertensive Rats (SHRs) animal model. Each group of SHRs (intact, control and experimental) contained 10 animals.
Figure 5The in vivo assessment of hepatoprotective properties for WPH–PS composition using Wistar rats with CCl4-induced hepatic injury animal model. Each group of Wistars (intact, control and experimental) contained 10 animals.